Insider buying of $4 million, including $1 million by the CEO at $645, signals strong confidence in Lilly’s pipeline: Mounjaro’s 37% sales growth and Zepbound’s projected $5 billion revenue by 2026 position Lilly to dominate the $100 billion obesity market. With a forward P/E of 50x, justified by 30% EPS growth, Lilly is a high-conviction buy for healthcare investors targeting 20%+ upside by 2026.
Selling 33% of an ETH bag reflects patterns....
Selling 33% of an ETH bag reflects patterns....
Eli Lilly’s Blockbuster Drug Growth in Q3 2023
testtest news
Eli Lilly’s Blockbuster Drug Growth in Q3 2023
Massive AI Expansion Across Creative Cloud Massive AI Expansion Across Creative Cloud
Eli Lilly’s Blockbuster Drug Growth in Q3 2023
Amazon is a top pick for a decade-long hold
